Glaukos (GKOS) Total Debt (2014 - 2021)

Glaukos' (GKOS) quarterly Total Debt came in at $279.3 million in Q2 2021, little changed on a QoQ basis from $279.0 million in Q1 2021.

Glaukos (GKOS) Total Debt (2014 - 2021) Analysis & Trends

Glaukos (GKOS) has 5 years of Total Debt data on file, last reported at $279.3 million in Q2 2021.

On a quarterly basis, Total Debt changed N/A year-over-year to $279.3 million in Q2 2021; TTM through Jun 2021 was $279.3 million, a N/A change from a year earlier, with the FY2020 full-year figure at $89.2 million, changed N/A from the prior year.
Total Debt for Q2 2021 stood at $279.3 million, roughly flat from $279.0 million in the prior quarter.
Over the last five years, Total Debt for GKOS reached as high as $279.3 million in Q2 2021 and fell as low as $89.2 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Abbott Laboratories	183.67 Bn	176.38 Bn	6.27 Bn	34.05 Bn
2	Stryker	128.91 Bn	126.03 Bn	3.81 Bn	14.72 Bn
3	Medtronic	108.84 Bn	99.62 Bn	6.41 Bn	27.96 Bn
4	Boston Scientific	68.57 Bn	67.12 Bn	3.61 Bn	11.03 Bn
5	Edwards Lifesciences	48.68 Bn	45.01 Bn	1.29 Bn	598.50 Mn
6	Dexcom	28.42 Bn	27.31 Bn	750.30 Mn	-
7	GE HealthCare Technologies	28.38 Bn	26.09 Bn	1.98 Bn	10.14 Bn
8	Smith & Nephew	26.94 Bn	26.36 Bn	-	3.18 Bn
9	Koninklijke Philips	25.50 Bn	22.38 Bn	2.07 Bn	9.48 Bn
10	Glaukos	8.79 Bn	8.68 Bn	117.23 Mn	-

Download Data